Last reviewed · How we verify
Mesenchymal Stem Cells
Mesenchymal stem cells promote tissue repair and modulate immune responses through secretion of anti-inflammatory factors and differentiation into specialized cell types.
Mesenchymal stem cells promote tissue repair and modulate immune responses through secretion of anti-inflammatory factors and differentiation into specialized cell types. Used for Graft-versus-host disease (GVHD), Tissue repair and regeneration, Inflammatory conditions.
At a glance
| Generic name | Mesenchymal Stem Cells |
|---|---|
| Also known as | Autologous MSC, MSC, MSCs, mesenchymal stomal cells, Mscs |
| Sponsor | Ottawa Hospital Research Institute |
| Drug class | Cell therapy |
| Modality | Biologic |
| Therapeutic area | Regenerative Medicine, Immunology |
| Phase | Phase 3 |
Mechanism of action
MSCs are multipotent stromal cells that can differentiate into various cell lineages (osteocytes, chondrocytes, adipocytes) to replace damaged tissue. They also secrete immunomodulatory cytokines and growth factors that reduce inflammation, promote angiogenesis, and suppress pathogenic immune responses, making them suitable for regenerative and immunological applications.
Approved indications
- Graft-versus-host disease (GVHD)
- Tissue repair and regeneration
- Inflammatory conditions
Common side effects
- Infusion-related reactions
- Infection
- Immunogenicity
Key clinical trials
- Phase 1 Study of VELGRAFT, a Living Cellular Construct, in the Management of Chronic Diabetic Foot Ulcers Which Have Attained Granulation Tissue (PHASE1)
- A Trial to Evaluate the Safety and Preliminary Efficacy of iMesenchymal Stromal Cells(iMSC) in Subjects With SR-aGVHD (NA)
- Evaluation of Allogenic Mesenchymal Stem Cell (MSC) Injection Therapy for Refractory Graft-versus-Host Disease (GVHD) Unresponsive to Conventional Treatments (PHASE2)
- cfMSC Therapy for Diabetes (PHASE1, PHASE2)
- Exosomes Effect on Visual Function in CVI
- Study on the Safety and Efficacy of Intratympanic Injection of Small Extracellular Vesicles Derived From Mesenchymal Stem Cells in Severe and Profound Sudden Sensorineural Hearing Loss (PHASE1, PHASE2)
- cfMSC Stem Cell Therapy Targeting COPD (PHASE1, PHASE2)
- Anterior Cruciate Ligament (ACL) Reconstruction With Autologous Fat Pad Derived Mesenchymal Stem Cells (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |